AQR Capital Management LLC Raises Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)

AQR Capital Management LLC lifted its position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) by 567.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 201,080 shares of the biopharmaceutical company's stock after purchasing an additional 170,960 shares during the period. AQR Capital Management LLC owned 0.19% of Revance Therapeutics worth $517,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Certuity LLC purchased a new stake in shares of Revance Therapeutics during the second quarter valued at approximately $26,000. Vanguard Personalized Indexing Management LLC bought a new position in Revance Therapeutics in the 2nd quarter valued at $33,000. Hsbc Holdings PLC purchased a new stake in shares of Revance Therapeutics during the 2nd quarter valued at $38,000. Nisa Investment Advisors LLC raised its stake in shares of Revance Therapeutics by 2,167.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 18,911 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 18,077 shares during the period. Finally, Sei Investments Co. boosted its holdings in shares of Revance Therapeutics by 52.5% in the 2nd quarter. Sei Investments Co. now owns 22,167 shares of the biopharmaceutical company's stock worth $57,000 after buying an additional 7,628 shares during the last quarter. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently issued reports on RVNC. Needham & Company LLC downgraded shares of Revance Therapeutics from a "moderate buy" rating to a "hold" rating in a report on Tuesday, August 13th. StockNews.com assumed coverage on shares of Revance Therapeutics in a report on Wednesday, October 9th. They issued a "hold" rating on the stock. Stifel Nicolaus reduced their price objective on Revance Therapeutics from $24.00 to $20.00 and set a "buy" rating for the company in a report on Friday, August 9th. William Blair reissued a "market perform" rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Finally, Guggenheim reaffirmed a "neutral" rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Nine research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, Revance Therapeutics has an average rating of "Hold" and an average target price of $10.29.

Revance Therapeutics Price Performance

Revance Therapeutics stock opened at $5.14 on Tuesday. The firm has a market capitalization of $538.77 million, a P/E ratio of -1.61 and a beta of 0.98. Revance Therapeutics, Inc. has a one year low of $2.30 and a one year high of $9.90. The business has a fifty day moving average price of $5.82 and a 200-day moving average price of $4.26.

Revance Therapeutics (NASDAQ:RVNC - Get Free Report) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.12. The company had revenue of $65.39 million during the quarter, compared to the consensus estimate of $66.30 million. During the same quarter in the prior year, the business earned ($0.80) EPS. The firm's revenue for the quarter was up 20.2% compared to the same quarter last year. Sell-side analysts expect that Revance Therapeutics, Inc. will post -1.53 earnings per share for the current fiscal year.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.